A 58-year-old woman was diagnosed with peritoneal epithelioid mesothelioma, postdebulking surgery. Peripheral blood showed neutrophilic leukocytosis with left-shifted granulopoiesis, anemia, and mild thrombocytosis (white blood cells [WBCs], 89 × 109/L; hemogloblin [Hb], 6.0 g/dL; platelets, 617 × 109/L). Four months later, she presented to our institution with liver metastasis, progressive marked left-shifted neutrophilic leukocytosis, and anemia (WBCs, 284 × 109/L; absolute neutrophil count, 272 × 109/L; Hb, 7.4 g/dL; platelets, 145 × 109/L) (panels A-B; Wright-Giemsa stain), concerning for myeloid neoplasm (MN) including myeloproliferative neoplasms (MPNs; chronic myeloid leukemia [CML], chronic neutrophilic leukemia [CNL]) or myelodysplastic syndrome/MPN. Bone marrow examination showed hypercellularity (95%) with left-shifted granulocytic hyperplasia without basophilia, eosinophilia, or morphologic dysplasia (panels C-D; hematoxylin & eosin stain [C], Wright-Giemsa stain [D]). No metastatic mesothelioma was identified. Serum granulocyte colony-stimulating factor (G-CSF) was normal. Myeloid precursors showed unremarkable immunophenotype by flow cytometry. Cytogenetic analysis showed diploid female karyotype. Fluorescence in situ hybridization was negative for BCR-ABL1. Next-generation sequencing (81-gene panel) including CSF3R/JAK2/CALR/MPL and SETBP1 showed no mutations. Thus, overall findings were in keeping with a marked paraneoplastic leukemoid reaction (LR) in response to metastatic mesothelioma.
LR is reactive/paraneoplastic left-shifted neutrophilic leukocytosis (WBCs, >50 × 109/L), and can mimic MN. Marked LR in the setting of mesothelioma is exceedingly rare and can be idiopathic or attributed to cytokine production (G-CSF/granulocyte macrophage colony-stimulating factor/interleukin-6) by tumor cells. This case highlights the comprehensive approach of correlating clinical presentation with morphology (no dysplasia, atypical megakaryocytes or abnormal monocytes, presence of Döhle bodies), flow cytometry (no aberrant myeloblasts/abnormal myeloid maturation), and absence of clonality by cytogenetic and molecular studies, helping to distinguish reactive marked LR from MNs.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal